Biocomposites, an international medical devices company that engineers, manufactures and markets products for use in infection management in bone and soft tissue, has won been two Queen’s Awards for Enterprise for Innovation and International Trade.
Biocomposites is one of only seven organisations nationally to achieve two Queen’s Awards in 2022.
Announced annually by Her Majesty the Queen, the awards follow a rigorous and competitive judging process and are bestowed on organisations that maintain the highest levels of business excellence.
Biocomposites employs over 200 people and specialises in the development of innovative calcium compounds for surgical use, targeting infection risks across musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, and podiatry.
Biocomposites has been recognised in the Innovation category for the development of STIMULAN Rapid Cure, a calcium sulphate antibiotic carrier that is approved for use in infected bone and soft tissue. STIMULAN was developed to meet the growing need to reduce infection rates in surgical procedures.
The company has also been recognised in the International Trade category for its growth in overseas sales. Over the last six years, sales have grown by more than 200% from sales of its products into 40 countries, including the United States, the Netherlands, China, Canada, and India.
Michael Harris, chief executive officer of Biocomposites, said: “The Queen’s Awards are the most prestigious business awards in the UK, and we are proud that Biocomposites has been honoured with two of them. It is very pleasing to see our relentless focus on research and development recognised with an innovation award for STIMULAN as well as recognition for our incredible growth in global markets. I would like to thank the entire team at Biocomposites whose dedication to innovation and helping patients has made this achievement possible.”
